# to Assess the Eradication Rate of 14-day Bismuth/Amoxicillin/PCAB Triple Therapy for the Treatment of Helicobacter Pylori Infection

> **NCT07142798** · NA · ENROLLING_BY_INVITATION · sponsor: **Kaohsiung Medical University** · enrollment: 200 (estimated)

## Conditions studied

- HELICOBACTER PYLORI INFECTIONS

## Interventions

- **DRUG:** Bismuth amoxilillin potassium

## Key facts

- **NCT ID:** NCT07142798
- **Lead sponsor:** Kaohsiung Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-09-26
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-08-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07142798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07142798, "to Assess the Eradication Rate of 14-day Bismuth/Amoxicillin/PCAB Triple Therapy for the Treatment of Helicobacter Pylori Infection". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT07142798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*